Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | MMP9 | P14780 | 6/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
| ▸ | MMP3 | P08254 | 2/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9596069 | 0.87 | BACE1 (0.41) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7060922 | 0.84 | MMP2 (0.48) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL6561338 | 0.82 | MMP2 (0.70) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL5191083 | 0.82 | MMP2 (0.70) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL15251807 | 0.82 | MMP2 (0.70) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7062243 | 0.81 | KDM4E (0.54) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7451466 | 0.79 | MMP13 (0.65) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7064175 | 0.78 | PFKFB3 (0.52) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7066382 | 0.77 | ITGAV (0.47) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7062972 | 0.76 | SLC1A3 (0.56) | MMP2MMP9MMP13MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | claimed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | MMP2 1807/4885MMP9 1513/4885MMP13 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.